|
KR20200130451A
|
|
Pharmaceutical composition for subcutaneous administration containing a drug and a variant of human hyaluronidase PH20
|
|
KR20210023798A
|
|
Novel hyaluronic acid-hydrolyzing enzyme mutant and pharmaceutical composition comprising same
|
|
WO2019125002A1
|
|
Novel growth hormone receptor antagonist and fusion protein thereof
|
|
KR20190074958A
|
|
Novel Growth Hormone Receptor Antagonists and Fusion Proteins Thereof
|
|
KR20190142111A
|
|
Method for production of coagulation factor VII/VIIa or fusion proteins thereof
|
|
KR20190108351A
|
|
Antibody specifically binding to FOLR1 and Use thereof
|
|
CA3018691A1
|
|
Antibody-drug conjugates comprising antibodies modified with metal ion-binding motifs
|
|
WO2017176007A1
|
|
Antibody-drug conjugate comprising modified antibody
|
|
WO2017065559A1
|
|
Method for producing fusion protein having igg fc domain
|
|
KR20170044594A
|
|
Method for manufacturing fusion proteins with IgG Fc domain
|
|
KR20170000356A
|
|
A stable liquid formulation of fusion protein with IgG Fc domain
|
|
KR101704379B1
|
|
Antibody-Drug Conjugate and Method of Producing the Same
|
|
US2016114036A1
|
|
Composition for stabilizing protein and pharmaceutical formulation comprising the same
|
|
CN104870019A
|
|
Composition for stabilizing fusion protein in which protein and fc domain are fused
|
|
KR20130097669A
|
|
Antibody variant with cysteine residues, antibody-drug conjugate comprising the antibody variant, and method of manufacturing thereof
|
|
KR20130029713A
|
|
New alpha-1 antitrypsin variant, method for producing the same and use thereof
|
|
WO2011043530A1
|
|
Glp-1 analog fusions, and composition for preventing or treating diabetes containing the fusions as an active ingredient
|
|
WO2010123290A2
|
|
In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
|
